MODIFICATION
A -- Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) - Modification 3
- Notice Date
- 8/30/2018
- Notice Type
- Modification/Amendment
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Acquisitions Management, Contracts, & Grants (AMCG), Office of the Assistant Secretary for Preparedness & Response (ASPR), Department of Health and Human Services, 330 Independence Ave. SW, G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- BAA-18-100-SOL-00003
- Point of Contact
- Oke Obi, D.B.A., Phone: 2022600625, Francine L. Hemphill, D.B.A., Phone: 2022059271
- E-Mail Address
-
Oke.Obi@hhs.gov, Francine.Hemphill@hhs.gov
(Oke.Obi@hhs.gov, Francine.Hemphill@hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- BAA-18-100-SOL-00003 - Amendment 3 - Changes List BAA-18-100-SOL-00003 - Amendment 3 Synopsis: Original Synopsis: October 16, 2017 Broad Agency Announcement, November 6, 2017 as: BAA 18 100-SOL-00003 This Broad Agency Announcement combines versions of three related Broad Agency Announcements (BARDA CBRN BAA, BARDA Influenza BAA, and BARDA SST BAA), which have been re-issued annually: BAA-16-100-SOL-00001 BAA-16-100-SOL-00002 BAA-16-100-SOL-00003 The Office of Acquisitions Management, Contracts, and Grants (AMCG) on behalf of the Office of Biomedical Advanced Research and Development Authority (BARDA) solicits proposals for the advanced research and development of medical countermeasures (MCM) for chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population. BARDA anticipates that Research and Development (R&D) activities awarded under this BAA will serve to advance candidate medical countermeasures towards licensure or approval by the U.S. Food and Drug Administration (FDA). This BAA will also serve to advance the knowledge and scientific understanding of candidates’ platform technologies, modeling and forecasting, and visual analytics. BARDA encourages the advanced research, development, and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents, emerging infectious diseases, and pandemic influenza. These efforts are in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the 2016 PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: https://www.phe.gov/Preparedness/mcm/phemce/Documents/2016-phemce-sip.pdf. The Pandemic and All Hazard Preparedness Act Pub. L. No. 109-417, 42 U.S.C. § 241 et seq. (PAHPA: http://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf) and The Pandemic and All Hazard Preparedness Reauthorization Act Pub. L. No. 113-5, (PAHPRA: http://www.gpo.gov/fdsys/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf) authorizes BARDA to (i) conduct ongoing searches for, and support calls for, potential qualified countermeasures and qualified pandemic or epidemic products; (ii) direct and coordinate the countermeasure and product advanced research and development activities of the Department of Health and Human Services; (iii) establish strategic initiatives to accelerate countermeasure and product advanced research and development (which may include advanced research and development for purposes of fulfilling requirements under the Federal Food, Drug, and Cosmetic Act or section 351 of this Act) and innovation in such areas as the Secretary may identify as priority unmet need areas; and (iv) award contracts, grants, cooperative agreements, and enter into other transactions, for countermeasure and product advanced research and development. Areas of Interest: The purpose of this Broad Agency Announcement (BAA) is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I. Research and Development Areas of Interest: 1. CBRN Vaccines 2. CBRN Antitoxins and Therapeutic Proteins 3. Antibacterials 4. Radiological/Nuclear Threat Medical Countermeasures 5. Chemical Threat Medical Countermeasures 6. Burn Medical Countermeasures 7. Diagnostics 8. Influenza and Emerging Infectious Diseases (IEID) Vaccines 9. Influenza and Emerging Infectious Diseases (IEID) Therapeutics 10. Respiratory Protective Devices 11. Ventilators 12. MCM Production Platform Systems 13. Modeling as an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats 14. Visual Analytics an Enabling Technology for Influenza, Emerging Infectious Disease, and CBRN Threats The Government intends to have a full & open competition for this requirement in the form of a BAA. The Government expects to make one or more awards, subject to the availability of funds. Pre-proposal Conference: A BAA Pre-Proposal Conference is scheduled during the BARDA Industry Day from November 7-8, 2017 in Washington, D.C. Advance registration is required. For additional information, and to register, please visit: https://www.medicalcountermeasures.gov/federal-initiatives/public-meetings-and-conferences/barda-industry-day-2017.aspx Contact Information: Comments to this announcement, referencing synopsis BAA-18-100-SOL-00003, may be submitted to the following email address: BARDA-BAA@hhs.gov Contracting Office Address: Department of Health and Human Services (HHS), Office of the Secretary (OS), Assistant Secretary for Preparedness and Response (ASPR), Office of Acquisitions Management, Contracts, and Grants (AMCG), 200 C Street SW, Washington, DC 20201 *** Amendment 1 The following areas are revised: Background (changed) AOI 1.4 (added) AOI 2.1; 2.2; 2.3 (changed) AOI 5.2 (added) AOI 7.1; 7.3 (changed) AOI 8; 8.1; 8.2 (changed) AOI 12.2 (changed) AOI 8; 9 (suspended until October 1, 2018) AOI 12; 13; 14 (suspended until further notice) *** Amendment 2 The following areas are revised: AOI 8; 9 (Emerging Infectious Diseases - suspended until October 1, 2018) *** Amendment 3 The following areas are revised: AOI 6.1; 6.2 (changed) AOI 8.1; 8.2 (changed) AOI 3; 7; 9; 12 (POC updated)
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/BAA-18-100-SOL-00003/listing.html)
- Place of Performance
- Address: To be determined based on proposals submitted., United States
- Record
- SN05063767-W 20180901/180830231153-161fa518ec3c88392bbca79d44d871b5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |